---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-004771"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2024-02-02T23:59:59+00:00"
generated_at: "2026-06-06T10:10:21.402452+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biofrontera defers ~$4.3-4.5M payment to Feb 29; warrants exercised for 888K shares

## Summary
- Payment due Jan 31, 2024 deferred to Feb 29, 2024 under amended addendum to license and supply agreement.
- Institutional investor exercised pre-funded warrants for 888,000 shares; all such warrants now exercised.
- Total outstanding shares post-exercise: 2,572,628.
- Amended addendum details payment schedule: $2.791M due Dec 20, 2023; remainder and ~$2.9M PO due Feb 29.
- Failure to make timely payments under schedule constitutes immediate material breach with no cure period.

## SEC filing metadata
- accession: 0001493152-24-004771
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2024-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315224004771/0001493152-24-004771-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315224004771/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-004771
- JSON: https://secwatch.observer/filing/0001493152-24-004771.json
- Plain text: https://secwatch.observer/filing/0001493152-24-004771.txt

## Key facts
- Material Agreements
  Biofrontera Inc. amended LSA with Biofrontera Pharma GmbH, Biofrontera Bioscience GmbH, Biofrontera AG (effective 2024-01-26).
  - Action: amendment
  - Agreement: supply
  - Counterparty: Biofrontera Pharma GmbH, Biofrontera Bioscience GmbH, Biofrontera AG
  - Effective: 2024-01-26
  source text: On January 29, 2024, Biofrontera Inc. (the “ Company ”) entered into an amendment and restatement (the “ Amendment ”), effective January 26, 2024, of an Addendum (the “ Addendum ”), entered into on December 12, 2023, to its Amended and Restated License and Supply Agreement, dated as of June 16, 2021 (as previously amended, the “LSA”), by and among the Company, Biofrontera Pharma GmbH (“Pharma”), and Biofrontera Bioscience GmbH (“Bioscience”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858685/000149315224004771/0001493152-24-004771-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.